Nanobiotix S.A.
NBTX
$3.88
$0.1153.06%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -12.58M | 13.07M | 39.20M | 35.88M | 32.54M |
| Total Other Revenue | 4.78M | 5.63M | 6.47M | 6.58M | 6.65M |
| Total Revenue | -7.80M | 18.70M | 45.67M | 42.46M | 39.19M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -7.80M | 18.70M | 45.67M | 42.46M | 39.19M |
| SG&A Expenses | 22.21M | 23.06M | 23.82M | 23.90M | 23.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.06M | 68.11M | 69.87M | 67.81M | 65.37M |
| Operating Income | -73.86M | -49.41M | -24.20M | -25.35M | -26.18M |
| Income Before Tax | -73.62M | -55.12M | -35.92M | -39.52M | -42.79M |
| Income Tax Expenses | 109.20K | 195.10K | 282.40K | 206.50K | 129.90K |
| Earnings from Continuing Operations | -73.73 | -55.32 | -36.20 | -39.72 | -42.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.73M | -55.32M | -36.20M | -39.72M | -42.92M |
| EBIT | -73.86M | -49.41M | -24.20M | -25.35M | -26.18M |
| EBITDA | -73.22M | -48.78M | -23.60M | -24.49M | -25.09M |
| EPS Basic | -1.56 | -1.20 | -0.83 | -1.01 | -1.19 |
| Normalized Basic EPS | -1.01 | -0.70 | -0.38 | -0.51 | -0.63 |
| EPS Diluted | -1.56 | -1.20 | -0.83 | -1.02 | -1.20 |
| Normalized Diluted EPS | -1.01 | -0.70 | -0.38 | -0.51 | -0.63 |
| Average Basic Shares Outstanding | 189.06M | 180.47M | 171.89M | 159.80M | 147.71M |
| Average Diluted Shares Outstanding | 189.06M | 180.47M | 171.89M | 159.80M | 147.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |